White Paper

A Guide To Plasmid Selection In Drug Discovery: Starting With The End In Mind

Source: Charles River

The first installment in a three-part whitepaper series exploring the challenges and considerations for cell and gene therapy development, from bench through commercial supply.

  • Early development – using the right material
  • Translation from development to clinic – reducing risk and timelines
  • Clinical to commercial – scalability and supply chain simplification

For many viral vector producers, transient transfection is the preferred route of vector production. Reliable supply of plasmid DNA is critical through all stages of the product life cycle, coding not only for the therapeutic gene and expression elements, but also the vector capsid and required replication genes. As such, production and supply approaches must be designed to meet the demands of the product.

Clinical development milestones are built on the foundations and achievements of previous phases. In this white paper, we discuss the importance of an effective strategy, working backwards from the end-goal: commercialization.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene